Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma

NCT00028600 Phase 2 COMPLETED

RATIONALE: Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. The donated stem cells may also help destroy any remaining cancer cells (graft-versus-tumor effect). PURPOSE: This phase II trial is studying how well autologous peripheral stem cell transplant followed by donor peripheral stem cell transplant works in treating patients with multiple myeloma.

Details

Lead sponsor	Alliance for Clinical Trials in Oncology
Phase	Phase 2
Status	COMPLETED
Enrolment	60
Start date	2001-11
Completion	2010-02

Conditions

• Multiple Myeloma
• Plasma Cell Neoplasm

Interventions

• filgrastim
• CD34+ cells
• cyclophosphamide
• fludarabine phosphate
• melphalan
• methotrexate
• tacrolimus

Primary outcomes

• Treatment-related mortality — 6 months

Countries

United States